Press Releases

Date Title and Summary View
Toggle Summary Aquinox Pharmaceuticals Completes US $18 Million Series C Financing
Positive Phase IIa results attract additional funds and new syndicate member to advance clinical development and strengthen management team
View HTML
Toggle Summary Aquinox Pharmaceuticals Initiates Two Phase IIa Clinical Studies in Airway Inflammation Following Successful Phase I
AQX-1125, a novel oral anti-Inflammatory compound, exhibits desirable properties for continued development
View HTML
Toggle Summary Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound
Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound Vancouver, British Columbia - January 5, 2011 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted
View HTML
Toggle Summary Aquinox Pharmaceuticals appoints Csaba Szabó, M.D., Ph.D., Vice President, Research and Chief Scientific Officer
Renowned pharmacologist joins world-leading research and development effort
View HTML
Toggle Summary Aquinox Pharmaceuticals Completes US $25 Million Series B Financing
New Investor - Pfizer Venture Investments - Joins Syndicate
View HTML
Toggle Summary Aquinox Pharmaceuticals Selects AQX-1125 as Lead Clinical Candidate
Aquinox Pharmaceuticals Selects AQX-1125 as Lead Clinical Candidate Vancouver, Canada and London, UK - October 11, 2009 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory
View HTML
Toggle Summary Aquinox Pharmaceuticals Inc. Names Board Member
Aquinox Pharmaceuticals Inc. Names Board Member Vancouver, British Columbia - July 10, 2008 Aquinox Pharmaceuticals is pleased to announce the addition of Dr. Daniel Levitt as an independent member of the Board of Directors. Dr. Levitt joined Cerimon Pharmaceuticals Inc.
View HTML
Toggle Summary With help from Mother Nature: A Novel New Drug Discovery May Revolutionize Treatment of Inflammatory Diseases and Leukemia
With help from Mother Nature: A Novel New Drug Discovery May Revolutionize Treatment of Inflammatory Diseases and Leukemia September 14, 2007 If you found yourself on a run-away train, would you want to switch on the brakes? Two Vancouver Coastal Health Research Institute (VCHRI) and University of
View HTML
Toggle Summary Aquinox Pharmaceuticals Inc. Completes US$14.5 million Series A financing
Ventures West Capital leads strong cross-border syndicate
View HTML